NCT
HOME CURRENT ARCHIVE COVID-19
HOME CURRENT ARCHIVE PUBLISH INSTRUCTIONS
FOR AUTHORS COVID-19 LOG IN / REGISTER HISTORY ABOUT US DIRECTORY CONTACT
Evaluation of the Xpert MTB RIF for tuberculosis diagnosis and detection of rifampicin resistance in vulnerable groups

Martínez-Romero, María Rosarys ,  Secretário-Chilemo, Tunyth ,  Lemus-Molina, Dihadenys ,  Mederos-Cuervo, Lilian María , Sardiñas-Aragón, Misleidis ,  García-León, Grechen ,  Echemendía-Font, Miguel ,  Díaz-Rodríguez, Raúl





2019, Number 3

2019; 78 (3)






ABSTRACT

Introduction: The emergence of tuberculosis (TB) and multidroresistant strains represents a problem for TB control. The objective was to evaluate the Xpert MTB/RIF (Xpert) in vulnerable groups (VG). Material and methods: We studied 82 pulmonary samples with Xpert indication, at the National Reference Laboratory, «Pedro Kourí» Institute, from May to October 2016. Sputum smear (AFB) and culture was performed, according to the laboratory procedures and Xpert according to the manufacturer’s standards. The results of the molecular assay were compared with the culture (detection of Mycobacterium tuberculosis) and proportions method (susceptibility to rifampicin). Results: The VG where most cases of TB were diagnosed was HIV positive (nine), followed by those previously treated (eight). Xpert detected TB in 21 cases, of which, eight was AFB negative. There was good agreement between Xpert and culture methods (greater than 92%) and excellent coincidence with the proportions method. Conclusions: The Xpert had a positive impact on the timely handling of cases. The excellent correlation between Xpert MTB/RIF and the proportions method demonstrates the utility of the system for the rapid assessment of rifampicin resistance as an indicator of TB - MDR.

KEYWORDS

Tuberculosis, Mycobacterium tuberculosis, Xpert Mtb/RIF, rifampicin.

REFERENCES

  1. Culqui DR, Rodríguez-Valín E, Martínez de Aragón MV. Epidemiología de las hospitalizaciones por tuberculosis en España: análisis del conjunto mínimo básico de datos 1999-2009. Enferm Infecc Microbiol Clin 2015;33(1):9-15. doi: 10.1016/j.eimc.2013.12.015.

  2. Vallego VP, Rodriguez JC, Searle MA et al. Ensayo Xpert/RIF en el diagnóstico de tuberculosis. Rev Chil Enferm Respir 2015; 31(2):127-131.

  3. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010;48(7):2495-2501. doi: 10.1128/JCM.00128-10.

  4. Barnard M, Gey van Pittius NC, van Helden V, Bosman M, Coetzee G, Warren RM. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012;50(11):3712-3716. doi: 10.1128/JCM.01958-12.

  5. Lawn SD, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013;13(4):349-361. doi: 10.1016/S1473-3099(13)70008-2.

  6. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014;21;(1):CD009593. doi: 10.1002/14651858.CD009593.pub3.

  7. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013;42(2):252-271. doi: 10.1183/09031936.00157212.

  8. Zeka AN, Tasbakan S, Cavusoglu C. Evaluation of GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampicin resistance in pulmonary and extrapulmonary speciments. J Clin Microbiol 2011;49(12):4138-4141. doi: 10.1128/JCM.05434-11.

  9. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadística de Salud. La Habana, Cuba: Anuario Estadístico de Salud; 2018. ISSN: 1561-4433.

  10. Lemus D, Echemendía M, Díaz R, Llanes MJ, Suárez L, Marrero A. Antituberculosis drug resistance in pulmonary isolates of Mycobacterium tuberculosis, Cuba 2012-2014. MEDICC Rev 2017;19(1):10-15.

  11. Resolución Ministerial No. 277. Ministerio de Salud Pública. Programa Nacional de Control de la Tuberculosis. Manual de Normas y Procedimientos. La Habana: Ciencias Médicas; 2013.

  12. World Health Organization. Xpert MTB/RIF implementation manual. Technical and operational ‘how-to’: practical considerations, 2014. France. WHO/HTM/TB/2014.1 Fecha de consulta: septiembre, 2018. Accesible en https://www.who.int/tb/publications/xpert_implem_manual/en/.

  13. World Health Organization. Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. WHO/HTM/TB/2013.16. Fecha de consulta: agosto, 2018. Accesible en https://www.who.int/tb/publications/xpert-mtb-rif-assay-diagnosis-policy-update/en/.

  14. Martínez-Romero MR, Sardiña-Aragón M, García-León G, Mederos-Cuervo L, Vega-Riverón B, Díaz-Rodríguez R. Evaluación del sistema automatizado BacT ALERT 3D para el aislamiento de micobacterias en el LNRTB-IPK. Neumol Cir Torax 2012;71(4):333-338.

  15. Muñoz L, Moure R, Porta N, et al. GeneXpert® for smear-negative pulmonary tuberculosis: does it play a role in low-burden countries? Diagn Microbiol Infect Dis 2013;75(3):325-326. doi: 10.1016/j.diagmicrobio.2012.11.011.

  16. Khanal S, Baral P, Shrestha M, et al. Yield of intensified tuberculosis case-finding activities using Xpert® MTB/RIF among risk groups in Nepal. Public Health Action 2016;6(2):136-141. doi: 10.5588/pha.16.0015.

  17. Lozano-Salazar JL, Plasencia-Asorey CC, Costa-Montané DM, Puente-Saní V. Coinfección por tuberculosis y virus de la inmunodeficiencia humana: confluencia de dos epidemias. MEDISAN 2012;16(9):1438-1450.

  18. De Paz DA, Potes L, Quiñónez E, et al.; Grupo de Investigación de Tuberculosis de la Fundación Valle del Lili. Resistencia a fármacos antituberculosis en pacientes coinfectados con tuberculosis y virus de la inmunodeficiencia humana, en un hospital de referencia de 2007 a 2010 en Cali, Colombia. Infectio 2012;16(3):161-165. doi: 10.1016/S0123-9392(12)70006-1.

  19. Peralta-Gómez I, Cabrera-Rodríguez MC, Gutiérrez-Díaz MJ. Coinfección TB/VIH: una amenaza para los programas de control de ambas enfermedades. Medicent Electrón 2015;19(3):160-162.

  20. Zarate E, Lobón I, Saavedra C, Castañeda M. Tuberculosis en nuevos escenarios: establecimientos penitenciarios. An Fac Med Lima 2005;66(2):148-158.

  21. Iram S, Zeenat A, Hussain S, Wasim Yusuf N, Aslam M. Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay- report from a developing country. Pak J Med Sci 2015;31(1):105-110. doi: 10.12669/pjms.311.6970.

  22. Peñata A, Salazar R, Castaño T, Bustamante J, Ospina S. Diagnóstico molecular de tuberculosis extrapulmonar y sensibilidad a rifampicina con un método automatizado en tiempo real. Biomédica 2016;36(Supl.1):78-89. doi: https://doi.org/10.7705/biomedica.v36i3.3088.

  23. Bajrami R, Mulliqi G, Kurti A, Lila G, Raka L. Comparison of GeneXpert MTB/RIF and conventional methods for the diagnosis of tuberculosis in Kosovo. J Infect Dev Ctries 2016;10(4):418-422. doi: 10.3855/jidc.7569.

  24. Agrawal M, Bajaj A, Bhatia V, Dutt S. Comparative study of GeneXpert with ZN stain and culture in samples of suspected pulmonary tuberculosis. J Clin Diagn Res 2016;10(5):DC09-12. doi: 10.7860/JCDR/2016/18837.7755.

  25. Ioannidis P, Papaventsis D, Karabela S, et al. Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results. J Clin Microbiol 2011;49(8):3068-3070. doi: 10.1128/JCM.00718-11.

  26. Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaître N. Comparison of the Xpert MTB/RIF test with an IS6110-TagMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol 2011;49(5):1772-1776. doi: 10.1128/JCM.02157-10.

  27. Marlowe EM, Novak-Weekley SM, Cumpio J, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 2011;49(4):1621-1623. doi: 10.1128/JCM.02214-10.

  28. Moure R, Muñoz L, Torres M, Santin M, Martín R, Alcaide F. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. J Clin Microbiol 2011;49(3):1137-1139. doi: 10.1128/JCM.01831-10.

  29. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicenter implementation study. Lancet 2011;377(9776):1495-1505. doi: 10.1016/S0140-6736(11)60438-8.

  30. Organización Panamericana de la Salud. Manual para el Diagnóstico Bacteriológico de la Tuberculosis. Parte 1. Manual de actualización de la baciloscopia, 2018.

  31. Arias MF, Herrera MT. Nuevos métodos para el diagnóstico de la tuberculosis. Rev Chil Enferm Respir 2016;32(4):254-259.

  32. Rockwood N, Abdullahi LH, Wilkinson RJ, Meintjes G. Risk factors for acquired rifamycin and isoniazid resistance: a systematic review and meta-analysis. PLoS One 2015;10(9):e0139017. doi: 10.1371/journal.pone.0139017.


2019, Number 3

2019; 78 (3)